An interesting company.
Somewhat of a wildcard. Main drug appears to generically improve kidney function. Being submitted to FDA for a specific orphan disease because that is the goto way to get a drug approved quickly. Seems likely to get approval. Wonder how much leeway insurance carriers will provide doctors to use this for other conditions with deteriorated kidney function. The inevitable high orphan drug price may be a deterrent.
Financials are a WAG for any company with no actively sold products. Stock price has been all over the place. Baring unforeseen problems, company has reached point where it is likely can bring product to market with no more dilutive capital raises.